BGPartner advises Memo Therapeutics on extension of Series C financing to CHF 45 million

BGPartner advised Memo Therapeutics Ltd, a late-stage biotech company developing a best-in-class BKV-neutralizing antibody for BKV infection in kidney transplantation, on the successful completion of its Series C extension financing. Memo Therapeutics Ltd raised a further CHF 20 million, bringing the total amount raised in this funding round to CHF 45 million. The Series C extension financing was led by Ysios Capital and Kurma Partners and was joined by existing investors.

The new funding will be used to bolster the clinical advancement of Memo Therapeutic’s lead asset, AntiBKV. There are more than 100,000 kidney transplants worldwide each year and 20,000 of these are at risk from developing BK virus associated nephropathy. With no disease modifying therapies available, there is an urgent need for a treatment. FDA fast track status has already been obtained.

BGPartner assisted Memo Therapeutics Ltd in all legal and negotiation matters in this transaction and is proud to have been advising Memo Therapeutics Ltd for several years already. The team was led by Oliver Gnehm (Partner) and consisted of Victoria Marty (Senior Associate) and Barbara Meise (Associate).

Click here for the complete media release.

More information about our legal and negotiation expertise can be found here.